MDACC Study No:2011-1124 ( NCT No: NCT01473901)
Title:A Phase I, Two-Stage, Multi-Center, Open-Label Dose-Escalation Study of BKM120 in Combination with Adjuvant Temozolomide and with Concomitant Radiation Therapy and Temozolomide in Patients with Newly Diagnosed Glioblastoma
Principal Investigator:John DeGroot
Treatment Agent:BKM120; Temozolomide
Study Status:Closed
Study Description:Unavailable
Hide details for General InformationGeneral Information

Disease Group:Brain; CNS
Phase of Study:Phase I
Treatment Agents:BKM120
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Novartis Pharmaceuticals Corporation
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:John DeGroot
Dept:Neuro Oncology
For Clinical Trial Enrollment:713-792-2883
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults